BRACAnalysis CDx® is an FDA-approved test used to identify patients with germline BRCA1/2 mutations who may be eligible for certain targeted therapies.
IHC Test to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab
Foresight® Carrier Screen detects a couple’s risk of passing down serious, inheritable health conditions to their child to guide informed planning and preparation.
The GeneSight® Psychotropic test analyzes how a patient’s genes may affect their outcomes with medications commonly prescribed to treat depression, anxiety, ADHD and other mental health conditions.
For patients with ovarian cancer, MyChoice® CDx examines an ovarian cancer tumor’s HRD status to help determine whether a patient may be a candidate for PARP inhibitor therapy.
MyRisk® Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.
Designed for everyone regardless of ancestry and BMI or ability to pay, the Prequel® Prenatal Screen can determine if a pregnancy is at an increased risk for a wide variety of chromosomal conditions as early as 10 weeks.
Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.
Our tests and screens reveal information to guide patients and providers to better health and well-being. Whether you’re searching for answers related to cancer risk, cancer treatment, prenatal care or mental health, Myriad screens and tests can help.